Longeveron Inc (LGVN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.81+3.50%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LGVN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance laromestrocel (Lomecel-B) as a treatment for Hypoplastic Left Heart Syndrome, targeting top-line Phase 2b clinical trial results in Q3 2026.
Stated as a priority in 2 of last 2 quarters. Management anticipates top-line Phase 2b clinical trial results for laromestrocel in HLHS in Q3 2026. The FDA has granted Orphan Drug, Fast Track, and Rare Pediatric Disease designations for this program. The trajectory is delivering as the trial progresses toward the expected data readout.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Topline results from the Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct therapy for HLHS are anticipated in September 2026.”
“Topline results from the Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct therapy for HLHS are anticipated in August 2026.”
Focus on securing strategic licensing partnerships across laromestrocel's four development programs to accelerate time to market and increase capital efficiency.
Stated as a priority in 2 of last 2 quarters. Management has emphasized a strategic repositioning toward capital efficiency and partnership development. Meetings with potential partners were held in Q2 2026. The company is actively pursuing collaborations but no specific partnership revenue or deals are reported yet, indicating ongoing efforts with limited substantive delivery so far.
“Members of senior management hosted meetings to explore potential partnership and strategic opportunities for the Company’s four stem cell development programs.”
“We have transitioned toward a more capital-efficient, asset-light operating model, with an increased focus on securing strategic licensing partnerships for our stem cell therapy laromestrocel.”
Maintain disciplined capital allocation and extend cash runway through cost management and capital raises to support ongoing operations into late 2026.
Stated as a priority in 2 of last 2 quarters. Cash and cash equivalents decreased from $15.8M in 2026-Q1 to $10.1M in 2026-Q2, with negative operating cash flow increasing from $4.37M to $5.65M. Management expects current cash to fund operations into Q4 2026 and plans to seek additional financing. The trajectory shows ongoing cash burn with active capital management efforts.
“We currently anticipate our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2026.”
“We currently anticipate our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2026.”
Implement a 1-for-10 reverse stock split to increase share price and regain compliance with Nasdaq's $1.00 minimum bid price requirement.
Newly stated in 2026-Q3. The company announced a 1-for-10 reverse stock split effective August 26, 2026, to regain Nasdaq compliance with the $1.00 minimum bid price. This is a structural regulatory action with no direct financial impact reported yet. The priority is newly stated and actioned.
Appoint Marie Washburn as CFO effective July 13, 2026, to support operational, financial, and accounting functions during key clinical milestones.
Newly stated in 2026-Q3. The company appointed Marie Washburn as CFO effective July 13, 2026, to strengthen leadership during a critical period with upcoming clinical trial results. This is a recent executive change with no direct financial metrics yet.
Over the trailing year it converted 0.81x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
24 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.